TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34305452

Group type: EXPERIMENTAL
Intervention: CT genotype of CD14 SNP rs2569190
Number of subjects: 1002

Group type: COMPARATOR
Intervention: All investigated genetic variants
Number of subjects: 1002
Study: 34305947

Group type: EXPERIMENTAL
Intervention: Immunopeptidome-guided peptide warehouse design for CLL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparative mass spectrometry-based immunopeptidome analyses of CLL samples
Number of subjects: 0
Study: 34305948

Group type: EXPERIMENTAL
Intervention: GC5107 (10% intravenous immunoglobulin) administered at doses ranging from 319 to 881 mg/kg body weight every 21 or 28 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: GC5107 (10% intravenous immunoglobulin)
Number of subjects: 49
Study: 34306222

Group type: EXPERIMENTAL
Intervention: Spontaneous quitting (no smoking in the last 7 days and did not plan the quit in advance)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Intermittent smoking (smoking on some days)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Smoke-free home/car policies
Number of subjects: 981
Study: 34306227

Group type: EXPERIMENTAL
Intervention: Tobacco cessation treatment (prescription for nicotine replacement therapy and referral to the quitline)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Usual-care control practices
Number of subjects: 1007
Study: 34306677

Group type: EXPERIMENTAL
Intervention: N-acetylglucosamine
Number of subjects: 50
Study: 34307126

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin (PLD) 35 mg/m²
Number of subjects: 50
Study: 34307188

Group type: EXPERIMENTAL
Intervention: Interferon-lambda 3 and 4 polymorphisms
Number of subjects: 0
Study: 34307246

Group type: EXPERIMENTAL
Intervention: Initial steroid treatment, dosage and duration not specified
Number of subjects: 0
Study: 34307397

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34307499

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right Ventricular Pacing
Number of subjects: 0
Study: 34307504

Group type: EXPERIMENTAL
Intervention: Plasma Purification Treatment
Number of subjects: 0
Study: 34307728

Group type: EXPERIMENTAL
Intervention: Blood culture positivity
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Time to positivity of blood cultures
Number of subjects: 325
Study: 34308137

Group type: EXPERIMENTAL
Intervention: Current or former smokers (active or former smokers)
Number of subjects: 5224

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 5224

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 5224
Study: 34308309

Group type: EXPERIMENTAL
Intervention: 1000 mg DHA per day
Number of subjects: 1100

Group type: COMPARATOR
Intervention: 200 mg DHA per day
Number of subjects: 1100
Study: 34308322

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black participants in the US
Number of subjects: 2102364

Group type: EXPERIMENTAL
Intervention: Hispanic participants in the US
Number of subjects: 2102364

Group type: EXPERIMENTAL
Intervention: Black participants in the UK
Number of subjects: 2102364

Group type: EXPERIMENTAL
Intervention: South Asian participants in the UK
Number of subjects: 2102364

Group type: EXPERIMENTAL
Intervention: Middle Eastern participants in the UK
Number of subjects: 2102364
Study: 34308366

Group type: EXPERIMENTAL
Intervention: Germline pathogenic and likely pathogenic (P/LP) variants testing
Number of subjects: 751
Study: 34308517

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34309015

Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34309174

Group type: EXPERIMENTAL
Intervention: CD22 CAR T cells
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Heightened inflammatory states
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Recognition and prevention of extended inflammation
Number of subjects: 3
Study: 34309408

Group type: EXPERIMENTAL
Intervention: Connectome-Based Models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cognitive assessments
Number of subjects: 0
Study: 34309636

Group type: EXPERIMENTAL
Intervention: Nilotinib 230 mg/m2 twice daily
Number of subjects: 58
Study: 34309846

Group type: EXPERIMENTAL
Intervention: Cam-FOLFOX4 (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus FOLFOX4)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cam-GEMOX (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus GEMOX)
Number of subjects: 92
Study: 34310027

Group type: EXPERIMENTAL
Intervention: Risk-prediction score based on chemotherapy intensity, time since diagnosis, and type of malignancy.
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Intermittent antibiotic prophylaxis (4.3 months to prevent one FN with bacteremia, 5.2 months to prevent one FN with SRE).
Number of subjects: 238

Group type: COMPARATOR
Intervention: Published rules for predicting FN.
Number of subjects: 238
Study: 34310102

Group type: EXPERIMENTAL
Intervention: VP2 mRNA expression measured by real-time polymerase chain reaction
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Molecular TCMR classifier
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: BKN probability classifier
Number of subjects: 102

Group type: COMPARATOR
Intervention: Histological assessment of TCMR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Assessment of tubulitis and inflammation
Number of subjects: 102
Study: 34310218

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 34310436

Group type: EXPERIMENTAL
Intervention: Biochemical resolution (total bilirubin [TB] ≤1 mg/dL and ALT <35 U/L)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Partial resolution (TB >1 mg/dL and/or ALT >35 U/L)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Exited healthy (resolved disease per study site report but without documented biochemical resolution)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Liver transplant
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: GGT <100 U/L at baseline
Number of subjects: 94
Study: 34310498

Group type: EXPERIMENTAL
Intervention: Power Cycling (PC) training program consisting of 30 bouts of 4 s at an all-out intensity, 3 times a week for 8 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Power Cycling (PC) training program
Number of subjects: 11
Study: 34310745

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel
Number of subjects: 0
Study: 34310835

Group type: EXPERIMENTAL
Intervention: One metastasectomy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Multiple local interventions
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Chemotherapy (1 to 5 courses)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No metastasectomy
Number of subjects: 220
Study: 34310871

Group type: EXPERIMENTAL
Intervention: Invasive NAVA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noninvasive NAVA
Number of subjects: 18

Group type: COMPARATOR
Intervention: NAVA (both invasive and noninvasive)
Number of subjects: 18
Study: 34311211

Group type: EXPERIMENTAL
Intervention: Low HER2 expression (IHC 1+, or IHC 2+/ISH negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IHC 2+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low HER2 expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: No HER2 expression (IHC score 0)
Number of subjects: 0
Study: 34311566

Group type: EXPERIMENTAL
Intervention: Solitaire stent-retriever
Number of subjects: 984
Study: 34311567

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Dependent patients
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Independent patients
Number of subjects: 801
Study: 34311765

Group type: EXPERIMENTAL
Intervention: Support for addiction services referrals
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Support for syringe service programs (SSP) referrals
Number of subjects: 305

Group type: COMPARATOR
Intervention: Support for addiction services based on district assignment
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Belief in methadone programs reducing crime
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Support for SSP based on age
Number of subjects: 305

Group type: COMPARATOR
Intervention: Support for SSP based on district assignment
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Belief in methadone programs reducing crime for SSP support
Number of subjects: 305

Group type: COMPARATOR
Intervention: Belief in SSPs increasing needlestick injury risk
Number of subjects: 305
Study: 34311780

Group type: EXPERIMENTAL
Intervention: Immunotherapy combinations with personalized vaccines, checkpoint inhibitors, targeted therapies, multikinase inhibitors, chemotherapies, and radiation
Number of subjects: 0
Study: 34312155

Group type: EXPERIMENTAL
Intervention: mHealth GupShup Potli (GSP) audio recordings
Number of subjects: 4608

Group type: EXPERIMENTAL
Intervention: IPC paper-based tools
Number of subjects: 4608

Group type: COMPARATOR
Intervention: Control group (unexposed women)
Number of subjects: 4608
Study: 34312201

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in children
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 1-2
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 4-5
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 7-8
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: COVID-19-compatible symptoms reported by children
Number of subjects: 2585

Group type: COMPARATOR
Intervention: Comparison of seroprevalence in children and adults
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Ratio of confirmed SARS-CoV-2 cumulative incidence-to-seropositive cases
Number of subjects: 2585
Study: 34312211

Group type: EXPERIMENTAL
Intervention: Neuromuscular ultrasonography (NMUS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nerve conduction study (NCS)
Number of subjects: 37
Study: 34312462

Group type: EXPERIMENTAL
Intervention: High doses of mb-IL21 ex vivo expanded donor-derived NK cells
Number of subjects: 25
Study: 34312483

Group type: EXPERIMENTAL
Intervention: Anti-GITR neutralizing antibodies
Number of subjects: 73

Group type: COMPARATOR
Intervention: Accelerated radiation therapy
Number of subjects: 73
Study: 34312544

Group type: EXPERIMENTAL
Intervention: Memory antigen-specific CD8 T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exhausted antigen-specific CD8 T cells
Number of subjects: 0
Study: 34312556

Group type: EXPERIMENTAL
Intervention: CAR T cells with dual targeting of CD19 and CD22
Number of subjects: 16

Group type: COMPARATOR
Intervention: CAR19 treatment
Number of subjects: 16
Study: 34312616

Group type: EXPERIMENTAL
Intervention: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Mitigation strategies including higher than expected student mask compliance, reduced room capacity, and phased reopening
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Number of subjects: 475
Study: 34312724

Group type: EXPERIMENTAL
Intervention: COVID-19 Lockdown (P20)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Pre-COVID period (P19)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Delay in ED presentation
Number of subjects: 123
Study: 34312919

Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in on-pump CABG
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in off-pump CABG
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Left internal thoracic arteries
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vein grafts to left anterior descending and diagonal arteries
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in right coronary territory (off-pump)
Number of subjects: 56
Study: 34313474

Group type: EXPERIMENTAL
Intervention: Monopolar no-touch radiofrequency ablation (RFA)
Number of subjects: 0
Study: 34313599

Group type: EXPERIMENTAL
Intervention: Dyson air purifiers (Dyson Pure Cool)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo Dyson filters
Number of subjects: 50
Study: 34313611

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 909
Study: 34313752

Group type: EXPERIMENTAL
Intervention: SAGIT instrument for CGE-DC
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: SAGIT instrument for clinician's therapeutic decision
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: SAGIT instrument for international guidelines
Number of subjects: 227

Group type: COMPARATOR
Intervention: CGE-DC non-controlled acromegaly
Number of subjects: 227
Study: 34313764

Group type: EXPERIMENTAL
Intervention: Machine-learning models using nonmodifiable variables
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Machine-learning models using directly modifiable variables
Number of subjects: 313

Group type: COMPARATOR
Intervention: Multivariate linear regression using directly modifiable variables
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Directly modifiable features (dietary factors)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Low stool pH
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Nonmodifiable factors (age, sex, ethnicity)
Number of subjects: 313
Study: 34314241

Group type: EXPERIMENTAL
Intervention: Prolieve Transurethral Thermodilatation
Number of subjects: 0
Study: 34314285

Group type: EXPERIMENTAL
Intervention: Strict social distancing protocols (T1)
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Discontinued social distancing protocols (T2)
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Higher health anxiety
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Reduction of maladaptive coping strategies and negative metacognitive beliefs
Number of subjects: 10061
Study: 34314483

Group type: EXPERIMENTAL
Intervention: Danicopan (100 to 200 mg thrice daily)
Number of subjects: 12
Study: 34315238

Group type: EXPERIMENTAL
Intervention: Patients with Takotsubo syndrome and atrial fibrillation (AF)
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Patients with Takotsubo syndrome without atrial fibrillation (AF)
Number of subjects: 1584
Study: 34315415

Group type: EXPERIMENTAL
Intervention: Opt-in screening for blood-borne viral infections (BBV) using finger prick testing and risk factor assessment via questionnaire.
Number of subjects: 886
Study: 34315419

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 266 mg
Number of subjects: 20
Study: 34315432

Group type: EXPERIMENTAL
Intervention: ECV-guided LGE analysis
Number of subjects: 110

Group type: COMPARATOR
Intervention: Manual LGE assessment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ECV-guided analysis
Number of subjects: 110
Study: 34315519

Group type: EXPERIMENTAL
Intervention: Low burden group (definition 1)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Low burden group (definition 2)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Low burden group (definition 3)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Aβ-negative group
Number of subjects: 318
Study: 34315540

Group type: EXPERIMENTAL
Intervention: External facilitation (EF)
Number of subjects: 6
Study: 34315767

Group type: EXPERIMENTAL
Intervention: Dilpacimab (3.75 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dilpacimab (various doses 1.25-7.5 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dilpacimab (various doses)
Number of subjects: 55
Study: 34315793

Group type: COMPARATOR
Intervention: Ripasudil 0.4% eye drops administered once daily for 1 week, then two times per day for 2 weeks in phase I, and two times per day for 12 weeks in phase II.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ripasudil 0.4% eye drops
Number of subjects: 0
Study: 34315821

Group type: EXPERIMENTAL
Intervention: Avelumab added to standard treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 43
Study: 34315890

Group type: EXPERIMENTAL
Intervention: Treatment-related amenorrhea (TRA)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Resumed menses after TRA
Number of subjects: 789
Study: 34316356

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No physical rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No physical rehabilitation
Number of subjects: 0
Study: 34316644

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 0
Study: 34317072

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study: 34318292

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34318295

Group type: EXPERIMENTAL
Intervention: Postpartum care interventions for low-income individuals
Number of subjects: 0
Study: 34319245

Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring System (RPMS) for 3 months; includes a tablet, weight scale, and pedometer providing daily educational content, weekly weigh-ins.
Number of subjects: 45
Study: 34319249

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) engagement
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Child life specialist support
Number of subjects: 55

Group type: COMPARATOR
Intervention: Reference group (no standardized support)
Number of subjects: 55
Study: 34319359

Group type: EXPERIMENTAL
Intervention: Targeted Behavioral Science Messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34319435

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin and 5-fluorouracil (TPF) induction chemotherapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Surgery after TPF chemotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Radical concurrent chemoradiotherapy after TPF chemotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: TPF chemotherapy alone
Number of subjects: 47
Study: 34319564

Group type: EXPERIMENTAL
Intervention: SNAC 3.6 g
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 34319808

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34319865

Group type: EXPERIMENTAL
Intervention: PHiD-CV/PCV13
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study: 34320161

Group type: EXPERIMENTAL
Intervention: Achieving 60% of energy delivery targets within 7 days
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Achieving 60% of protein delivery targets within 7 days
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Achieving targets within the first 7 days
Number of subjects: 1844
Study: 34320207

Group type: EXPERIMENTAL
Intervention: Burgers, Fries, & Soft Drinks dietary pattern
Number of subjects: 14099

Group type: EXPERIMENTAL
Intervention: Fish dietary pattern
Number of subjects: 14099

Group type: EXPERIMENTAL
Intervention: White Rice, Beans, & Red Meats dietary pattern
Number of subjects: 14099

Group type: EXPERIMENTAL
Intervention: Years living in the United States
Number of subjects: 14099
Study: 34320287

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 41
Study: 34320286

Group type: EXPERIMENTAL
Intervention: Metformin, metformin plus rosiglitazone, or metformin plus intensive lifestyle intervention during the initial trial; transitioned to metformin with or without insulin during follow-up.
Number of subjects: 500
Study: 34320342

Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of p38 MAPK or PRMT1
Number of subjects: 0

Group type: COMPARATOR
Intervention: High levels of p38 MAPK and PRMT1
Number of subjects: 0
Study: 34320504

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment
Number of subjects: 2282
Study: 34320557

Group type: EXPERIMENTAL
Intervention: High exercise volume group (≥150 min/wk)
Number of subjects: 38
Study: 34320785

Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM) 25 mg weekly and Lenalidomide (LEN) 20 mg on days 1-21 every 28 days
Number of subjects: 111
Study: 34320839

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34320940

Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiosurgery (SRT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Postoperative stereotactic radiotherapy
Number of subjects: 17
Study: 34320949

Group type: EXPERIMENTAL
Intervention: Percutaneous transvenous mitral commissurotomy (PTMC)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Immediate post-PTMC mitral valve area (IMVA) ≥ 2 cm
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Continuing secondary antibiotic prophylaxis
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation rhythm
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Wilkins echocardiographic score > 8
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Higher pre-procedural systolic pulmonary arterial pressure
Number of subjects: 186
Study: 34320980

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoid treatment (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34321095

Group type: EXPERIMENTAL
Intervention: 6-month home-based physical training and respiratory rehabilitation program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 39
Study: 34321280

Group type: EXPERIMENTAL
Intervention: Pexidartinib (600-1000 mg daily) and Sirolimus (2-6 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pexidartinib and Sirolimus combination therapy
Number of subjects: 24
Study: 34321407

Group type: EXPERIMENTAL
Intervention: Corvis Biomechanical Index (CBI) beta
Number of subjects: 448